Asia Pacific Hematuria Treatment Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Treatment (Drugs, Therapies, and Others), Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation), Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger’s Hematuria), End User (Hospitals, Clinics, and Ambulatory Surgical Centers, and Others)


No. of Pages: 181    |    Report Code: TIPRE00026249    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Buy Now
Asia Pacific Hematuria Treatment Market
Buy Now

Market Introduction

Hematuria is a medical condition where presence of blood is found in the urine. Generally, urine does not contain RBC and hence this can result in serious issue that may also cause kidney stones, urinary tract infection and other inherited diseases.

Moreover, the high prevalence hematuria associated indications is expected to bolster the market growth during the forecast period. However, undiagnosed cases of associated indications limit the growth of the Asia Pacific hematuria treatment market.

The COVID-19 outbreak has severely affected the tourism industry and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission. All these factors impacted moderately on hematuria treatment market for a short period of time due to restrictions on the supply chain as well as limited manufacturing capabilities. Renal involvement in COVID -19 patients may have a wide range of manifestations, including hematuria, proteinuria, pyuria, and acute kidney injury (AKI). Proteinuria and hematuria have been reported to have a higher prevalence of COVID 19 than AKI. On the other hand, AKI is currently a disturbing sign of hospitalized COVID 19 patients and a major risk factor for death. Therefore, the hematuria treatment market is positively affected by COVID19.

Market Overview and Dynamics

The Asia Pacific hematuria treatment market is projected to reach US$ 257.6 million by 2028 from US$ 211.0 million in 2021; it is anticipated to grow at a CAGR of 2.9% from 2021 to 2028. Healthcare expenditure has considerably increased due to the rising prevalence of chronic indications. The governments of various economies are investing substantially in improving the healthcare infrastructure. Moreover, patients in developed economies are becoming aware of the possible treatments and availability of reimbursement for the hematuria treatment. Hematuria is among the initial indications of chronic diseases such as blood cancer, bladder cancer, and kidney cancer. These diseases are covered under various health insurance policies that help the easy treatment of the patients and reduce the financial burden for healthcare. Thus, improving healthcare expenditure and awareness among the patients about the treatment is driving the Asia Pacific hematuria treatment market.

Key Market Segments

In terms of type, the macroscopic hematuria segment accounted for the largest share of the Asia Pacific hematuria treatment market in 2020. In terms of treatment, the drugs segment accounted for the largest share of the Asia Pacific hematuria treatment market in 2020. In terms of indication, the urinary tract infection segment accounted for the largest share of the Asia Pacific hematuria treatment market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Asia Pacific hematuria treatment market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the hematuria treatment market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH.

Reasons to Buy Report

  • To understand the Asia Pacific hematuria treatment market landscape and identify market segments that are likely to guarantee a strong return
  • To comprehend the ever-changing market landscape and stay ahead in competition
  • To efficiently plan merger and acquisition, and partnership deals in the Asia Pacific hematuria treatment market by identifying segments with the most promising probable sales
  • To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
  • To obtain market revenue forecast of the Asia Pacific hematuria treatment market based on various segments for the period 2021–2028

ASIA PACIFIC HEMATURIA TREATMENT MARKET SEGMENTATION

By

Treatment

  • Drugs
  • Therapies
  • Others

By Indication

  • Urinary Tract Infections
  • Kidney Stones
  • Urethritis
  • Blood Cancer
  • Bladder Stones
  • Prostate Cancer
  • Cystitis
  • Trauma
  • Vigorous Exercise
  • Polycystic Kidney Disease
  • Endometriosis
  • Menstruation

By Type

  • Macroscopic Hematuria
  • Microscopic Hematuria
  • Idiopathic Hematuria
  • Jogger’s Hematuria

By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASC's)
  • Others

By Country

  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific

Companies Mentioned

  1. AstraZeneca
  2. Bristol-Myers Squibb Company
  3. F. HOFFMANN-LA ROCHE LTD.
  4. GlaxoSmithKline plc.
  5. Janssen Pharmaceuticals
  6. Merck & Co., Inc.
  7. Novartis AG
  8. Pfizer Inc.
  9. Sun Pharmaceutical Industries Ltd
  10. Boehringer Ingelheim International GmbH

Asia Pacific Hematuria Treatment Strategic Insights

Strategic insights for the Asia Pacific Hematuria Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/asia-pacific-hematuria-treatment-market-strategic-framework.webp
Get more information on this report

Asia Pacific Hematuria Treatment Report Scope

Report Attribute Details
Market size in 2021 US$ 211.0 Million
Market Size by 2028 US$ 257.6 Million
Global CAGR (2021 - 2028) 2.9%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Treatment
  • Drugs
  • Therapies
By Indication
  • Urinary Tract Infections
  • Kidney Stones
  • Urethritis
  • Blood Cancer
  • Bladder Stones
  • Prostate Cancer
  • Cystitis
  • Trauma
  • Vigorous Exercise
  • Polycystic Kidney Disease
  • Endometriosis
  • Menstruation
By Type
  • Macroscopic Hematuria
  • Microscopic Hematuria
  • Idiopathic Hematuria
  • Jogger's Hematuria
By End User
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Get more information on this report

    Asia Pacific Hematuria Treatment Regional Insights

    The geographic scope of the Asia Pacific Hematuria Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/asia-pacific-hematuria-treatment-market-geography.webp
    Get more information on this report

    The List of Companies - Asia Pacific Hematuria Treatment Market

    1. AstraZeneca
    2. Bristol-Myers Squibb Company
    3. F. HOFFMANN-LA ROCHE LTD.
    4. GlaxoSmithKline plc.
    5. Janssen Pharmaceuticals
    6. Merck & Co., Inc.
    7. Novartis AG
    8. Pfizer Inc.
    9. Sun Pharmaceutical Industries Ltd
    10. Boehringer Ingelheim International GmbH
    Frequently Asked Questions
    How big is the Asia Pacific Hematuria Treatment Market?

    The Asia Pacific Hematuria Treatment Market is valued at US$ 211.0 Million in 2021, it is projected to reach US$ 257.6 Million by 2028.

    What is the CAGR for Asia Pacific Hematuria Treatment Market by (2021 - 2028)?

    As per our report Asia Pacific Hematuria Treatment Market, the market size is valued at US$ 211.0 Million in 2021, projecting it to reach US$ 257.6 Million by 2028. This translates to a CAGR of approximately 2.9% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Hematuria Treatment Market report typically cover these key segments-

    • Treatment (Drugs, Therapies)
    • Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, Menstruation)
    • Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, Jogger's Hematuria)
    • End User (Hospitals, Clinics, Ambulatory Surgical Centers)

    What is the historic period, base year, and forecast period taken for Asia Pacific Hematuria Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Hematuria Treatment Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Hematuria Treatment Market?

    The Asia Pacific Hematuria Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • GlaxoSmithKline plc.
  • Janssen Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim International GmbH
  • Who should buy this report?

    The Asia Pacific Hematuria Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Hematuria Treatment Market value chain can benefit from the information contained in a comprehensive market report.